As Hispanic Heritage Month comes to a close, we are proud to spotlight another team member making her mark in #STEM. Hear from Eve Arias-LiPuma, Sr. QA Learning Specialist, about her favorite things about her culture. #HispanicHeritageMonth
REGENXBIO
生物技术研究
Rockville,Maryland 33,043 位关注者
Seeking to improve lives through the curative potential of gene therapy.
关于我们
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
- 网站
-
https://www.regenxbio.com
REGENXBIO的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Rockville,Maryland
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Biotechnology、Biopharmaceuticals和Gene Therapy
地点
-
主要
9804 Medical Center Dr
US,Maryland,Rockville,20850
REGENXBIO员工
动态
-
Thank you to the Alliance for Regenerative Medicine for another great Meeting on the Mesa! It was great to join fellow innovators in cell and gene therapy and discuss how we’re advancing science and industry for patients.?#CGMesa24
-
Today on #WorldSightDay, we join the eye care community to recognize the fight against vision loss. At REGENXBIO, our teams are working diligently to advance potential new therapies for wet AMD and diabetic retinopathy, two leading causes of vision loss globally. To honor this day, our team stepped into the shoes of those living with low vision by volunteering with Be My Eyes, an app connecting visually impaired individuals with sighted volunteers for real-time assistance. Learn more: https://www.bemyeyes.com/
-
REGENXBIO is proud to sponsor #CGMesa24 and join fellow experts and leaders in the cell and gene therapy sector. Join CEO Curran Simpson and Chief Scientific Officer Olivier Danos at the Alliance for Regenerative Medicine's Meeting on the Mesa as they discuss developments and innovations in #cellandgenetherapy. https://lnkd.in/eiUpMy4
-
At our recent all company meeting, we announced our President’s Award winner, Matt Stone! Matt’s focus on the patients we serve allows him to lead our Clinical Supply teams with remarkable innovation and efficiency. Join us in congratulating Matt for this well-deserved recognition!
-
Last week at our all company meeting, we welcomed Sheryl Marrazzo, a dedicated Duchenne mother, advocate, and Community Outreach Coordinator at CureDuchenne. Sheryl shared her family’s powerful story and how they choose to live life to the fullest, even in the face of challenges. Thank you, Sheryl, for joining us and for inspiring us all!?
-
October is Blindness Awareness Month. At REGENXBIO, we are dedicated to developing gene therapies that have the potential to transform how vision-threatening diseases like wet AMD and diabetic retinopathy are treated. Let’s continue to advocate for vision health. #BlindnessAwarenessMonth
-
This Hispanic Heritage Month, we are proud to spotlight our incredible team members making their mark in #STEM. Hear from Leiby Soto, our amazing Administrative Assistant and Receptionist, about how she brings her perspective and culture to REGENXBIO. #HispanicHeritageMonth
-
REGENXBIO will participate in Chardan’s 8th Annual Genetic Medicines Conference. Learn more: https://lnkd.in/enPcs_R3